8-K: Venus Concept Reports Wider Q3 Loss, Unveils Venus NOVA

Venus Concept Inc. reported an increased net loss for the third quarter of 2025, alongside the significant announcement of FDA clearance for its new multi-application Venus NOVA platform.

Summary

• Total revenue for Q3 2025 was $13.8 million, an 8% decrease year-over-year and 12% quarter-over-quarter.
• The decline was primarily due to a delay in the pending sale of the Venus Hair Business.
• GAAP net loss for Q3 2025 was $22.5 million, significantly wider than the $9.3 million loss in Q3 2024.
• Adjusted EBITDA loss for Q3 2025 was $7.8 million, compared to $5.9 million in Q3 2024.
• Energy Based Device (EBD) systems sales showed signs of stabilization, increasing 2% year-over-year to $9.6 million.
• The company received FDA 510(k) clearance for Venus NOVA, a new multi-application platform for non-invasive body and skin treatments.
• Debt reduction efforts included exchanging $6.5 million and $11.5 million of subordinated convertible notes for Series Y preferred stock in July and October 2025, respectively, reducing total debt by 24% compared to December 31, 2024.
• Cash and cash equivalents increased to $5.9 million as of September 30, 2025, from $4.3 million at December 31, 2024, while total debt obligations decreased to $30.1 million from $39.7 million over the same period.
• No financial guidance was provided for fiscal year 2025 due to ongoing strategic evaluations and market uncertainties.

Sentiment

Score: 4

Explanation: While the company reported a significant widening of its net loss and a decline in overall revenue, the stabilization of EBD sales, successful FDA clearance of a new flagship product (Venus NOVA), and substantial debt reduction efforts provide some positive momentum. The delay in the Hair Business sale and lack of financial guidance add uncertainty.

Positives

• Energy Based Device (EBD) systems sales showed signs of stabilization, increasing 2% year-over-year to $9.6 million.
• Received FDA 510(k) clearance for Venus NOVA, a next-generation multi-application platform, marking the first product launch from the new R&D strategy.
• Successfully executed debt-to-equity exchanges totaling $18.0 million ($6.5 million in July and $11.5 million in October 2025), reducing total debt by 24% compared to December 31, 2024.
• Cash and cash equivalents increased to $5.9 million as of September 30, 2025, from $4.3 million at December 31, 2024.
• Operating expenses showed modest year-over-year increase, reflecting continued progress in cost containment and streamlining operations.
• R&D expenses decreased by 24% year-over-year, indicating a focused R&D strategy.
• The Venus NOVA is positioned to address the growing market for GLP-1 medication users experiencing skin laxity and body contour irregularities.

Negatives

• Total revenue for Q3 2025 decreased by 8% year-over-year to $13.8 million, and 12% quarter-over-quarter.
• GAAP net loss for Q3 2025 widened significantly to $22.5 million, compared to a $9.3 million loss in Q3 2024.
• Adjusted EBITDA loss increased to $7.8 million in Q3 2025 from $5.9 million in Q3 2024.
• Gross profit decreased by 11% to $8.8 million, and gross margin declined to 64.0% from 66.1% year-over-year.
• The Venus Hair Business revenue was negatively impacted by a delay in its pending sale, contributing to overall revenue decline.
• Operating loss increased to $9.5 million in Q3 2025 from $7.2 million in Q3 2024.
• The company is not providing financial guidance for fiscal year 2025 due to market uncertainties and ongoing strategic evaluations.
• The company is involved in a dispute with the Canada Revenue Agency regarding a $418,000 repayment request for CEWS claims.

Risks

• Challenges with the counterparty in closing the definitive agreement to sell the Venus Hair Business to MHG Co. Ltd., requiring assistance from the Delaware Court of Chancery.
• Global macro environment continues to challenge the aesthetics market.
• Customer uncertainty about the economic environment and tighter third-party lending practices negatively impacted capital equipment sales.
• Impact of U.S. tariffs on devices imported into the U.S. market.
• Higher device system costs of goods sold tracing to manufacturing overheads spread over a lower volume base.
• Ongoing evaluation of strategic alternatives with various interested parties to maximize shareholder value.
• Assessment of potential trade disruptions.
• Risks and uncertainties described under Part II Item 1A Risk Factors in Quarterly Reports on Form 10-Q and Part I Item 1A Risk Factors in Annual Report on Form 10-K for fiscal year ended December 31, 2024.
• Dispute with the Canada Revenue Agency regarding a $418,000 repayment request for CEWS claims.
• A provision made under the Voluntary Correction Plan to account for a discrepancy noted by the IRS upon review of the company's 401(K) plan.

Future Outlook

The company is targeting sequential growth in the fourth quarter of 2025, partly fueled by a limited commercial launch of the Venus NOVA in December. Management anticipates the U.S. commercial introduction of Venus NOVA to contribute to the company's long-term growth profile as it further penetrates the multi-billion-dollar body and skin market. However, no specific financial guidance for fiscal year 2025 is being provided due to ongoing strategic evaluations, active dialogue with lenders and investors, and potential trade disruptions.

Management Comments

• "Our third quarter results reflect our continued solid execution in a difficult environment for all companies." Rajiv De Silva, CEO
• "Our focus remains on positioning the Company for long-term success by managing our cash burn and making targeted investments to support our future growth." Rajiv De Silva, CEO
• "We are very encouraged by the signs of stabilization in our EBD business." Rajiv De Silva, CEO
• "We were especially pleased to announce FDA 510(k) clearance for our new Venus NOVA on November 10th the first product launch from our new, focused R&D strategy." Rajiv De Silva, CEO
• "We are targeting sequential growth in the fourth quarter fueled, in part, by a limited commercial launch of this innovative new body and skin system in December." Rajiv De Silva, CEO
• "Our balance sheet and capital structure transformation carried on this quarter through multiple transactions including amendments to increase available financing capacity under our existing bridge loan facility and a debt-to-equity exchange transaction totaling $11.5 million in converted debt." Rajiv De Silva, CEO
• "While the global macro environment continues to challenge the aesthetics market, the Venus team is engaged, focused and determined." Rajiv De Silva, CEO
• "We continue to appreciate the support of Madryn Asset Management, LP as we continue our turnaround." Rajiv De Silva, CEO
• "Unfortunately, we have experienced challenges with our counterparty in closing this transaction [Venus Hair Business sale] and have sought the assistance of the Delaware Court of Chancery to aid in this respect." Rajiv De Silva, CEO
• "Venus NOVA reflects the evolution of Venus Concepts commitment to science-based innovation, intelligent technology, and practice growth." Rajiv De Silva, CEO
• "Our product portfolio will continue to evolve and deliver more than just leading device performance, shifting towards a focus on total practice performance." Rajiv De Silva, CEO
• "Venus NOVA embodies the convergence of intelligent technology and proven clinical science." Melissa Kang, CPO
• "Venus NOVA is uniquely positioned to enhance body transformation journeys, including for those taking GLP-1 medications and experiencing skin laxity, facial volume loss, and body contour irregularities." Melissa Kang, CPO
• "We expect GLP-1 usage to grow to more than 32 million patients globally by 2030, and we are excited to offer our innovative, comprehensive technologies to support and address the unmet needs of our existing and future customers." Melissa Kang, CPO

Industry Context

The medical aesthetic technology industry is currently facing challenges from the global macro environment, impacting capital equipment sales due to customer uncertainty and tighter third-party lending. Despite this, Venus Concept is strategically positioning itself with new product innovations like Venus NOVA, which targets emerging trends such as the growing demand for non-invasive treatments, particularly for individuals using GLP-1 medications who may experience related aesthetic concerns like skin laxity. The company's focus on R&D and comprehensive solutions aims to capture a share of the multi-billion-dollar body and skin market, aligning with broader industry shifts towards advanced, intelligent aesthetic technologies and holistic practice performance.

Comparison to Industry Standards

• The company's gross margin of 64.0% in Q3 2025, while a decrease from 66.1% in the prior year, should be assessed against industry averages for medical aesthetic device manufacturers, which can vary widely based on product mix, R&D intensity, and sales channels.
• The 2% year-over-year growth in EBD systems sales, despite an overall revenue decline, suggests a segment performing better than the company's average, potentially indicating resilience in core aesthetic device demand compared to the broader market.
• The introduction of Venus NOVA, with its integrated technologies like Adaptive EMS, Multi-Polar RF, PEMF, and Advanced VariPulse, positions Venus Concept to compete with other multi-platform aesthetic device providers such as Cynosure, InMode, and BTL Aesthetics, which also offer comprehensive solutions for body contouring and skin treatments.
• The strategic focus on addressing the needs of GLP-1 medication users (projected 32 million patients by 2030) with Venus NOVA demonstrates an attempt to tap into a significant and growing market segment, potentially differentiating it from competitors who may not have explicitly tailored solutions for this demographic.

Legal Proceedings

• Sought assistance from the Delaware Court of Chancery regarding challenges with the counterparty in closing the sale of the Venus Hair Business.
• Disputes a Canada Revenue Agency (CRA) assessment requesting repayment of $418,000 for Canada Emergency Wage Subsidy (CEWS) claims made in 2020-2021 and intends to challenge this matter through the Tax Court or Judicial Review.
• A provision has been made under the Voluntary Correction Plan to account for a discrepancy noted by the IRS upon review of the company's 401(K) plan.

Related Party Transactions

• Exchanged $6.5 million and $11.5 million of subordinated convertible notes held by affiliates of Madryn Asset Management, LP for Series Y preferred stock. Madryn Asset Management, L.P. is also mentioned as a leading healthcare industry growth equity investor backing Venus Concept and providing financial support.

Stakeholder Impact

• Shareholders: Experience significant net losses and dilution from debt-to-equity conversions, but also potential long-term value from new product launches (Venus NOVA) and debt reduction. Uncertainty from delayed Hair Business sale and lack of guidance.
• Creditors (Madryn Asset Management, LP): Participated in debt-to-equity exchanges, converting debt into preferred stock, indicating continued support and a restructured financial relationship.
• Customers: Will benefit from the introduction of the Venus NOVA, offering advanced non-invasive body and skin treatments, potentially enhancing clinic offerings and patient outcomes.
• Employees: The company's focus on cost containment and streamlining operations, along with R&D strategy, could impact resource allocation and job roles, though not explicitly detailed.
• Suppliers: Potential impact from tighter third-party lending practices affecting capital equipment sales.

Next Steps

• Limited commercial launch of Venus NOVA in the United States in December 2025.
• Global rollouts of Venus NOVA planned throughout 2026 and beyond.
• Continued dedicated pursuit of closing the sale of the Venus Hair Business, including ongoing engagement with the Delaware Court of Chancery.
• Ongoing evaluation of strategic alternatives with various interested parties to maximize shareholder value.
• Continued implementation of turnaround plans, including debt restructurings and financings.
• Management will host a conference call on November 13, 2025, to discuss the Q3 results.

Key Dates

Recommendation

The company presents a mixed bag of results. While the significant widening of the net loss and revenue decline are concerning, the stabilization of EBD sales and the successful FDA clearance of the Venus NOVA are positive developments that could drive future growth. The substantial debt reduction through conversions is a crucial step in improving the balance sheet. However, the delay in the Hair Business sale and the absence of financial guidance introduce considerable uncertainty. Investors should hold to observe the commercial rollout of Venus NOVA, the resolution of the Hair Business sale, and the impact of ongoing turnaround strategies before making further investment decisions.

Keywords

Medical Aesthetic Technology, Venus NOVA, FDA Clearance, Q3 Earnings, Financial Results, Debt Restructuring, Body Contouring, Skin Treatments, Hair Restoration, Aesthetic Devices, NASDAQ: VERO, Madryn Asset Management, GLP-1, EMS, Radio Frequency, PEMF